itb-med is developing the proprietary antagonistic cd2-directed monoclonal antibody, tcd601 (siplizumab), for several indications. itb-med is wholly committed to advancing and exploring the potential of tcd601, with a particular focus on its applications in transplantation and autoimmunity. the efforts extend to comprehensive worldwide clinical trials. itb-med is actively investigating further preclinical therapies to expand the reach of its novel immune-modulating approaches.
Company Information
- Industry
- Biotechnology Research
- Company Type
- Privately Held
- Founded
- 2016
- Employee Range
- 11-50
- Revenue Range
- Not available
Location
- Address
- 110 e 59th st
- City
- New York
- Region
- Postal Code
- 10022
- Country
- United States Of America
Specialties
Transplantation SurgeryImmunologyMonoclonal Antibodies
Web Presence
Websiteitb-med.com
LinkedIn1,371 followers
